P/B
17
Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
$12B
Market Cap • 9/15/2026
1998
(28 years)
Founded
2004
(22 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
14,4
P/EBITDA
1418,7
P/OCF
109,2
P/FCF
112
P/E
263,9
BVPS
6,1
EPS
0,4
Market Cap
Market Cap
12B
EV
11,7B
EV/Revenue
14,1
EV/EBITDA
1383,3
EV/EBIT
1823,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0,7%
Total Yield
0,7%
Payout
0%
Retained Earnings
654,6M
Profitability
Gross Margin
98,3%
EBITDA Margin
1%
EBIT Margin
—
Net Margin
6,6%
D&A/EBITDA
0%
R&D/Revenue
30,6%
Capex/Revenue
0,3%
Capex/D&A
136,3%
Capex/OCF
2,5%
SBC/OCF
87,6%
% PPE
1,3%
% Goodwill
0%
ROE
8,2%
ROIC
3,3%
Growth
CAGR Revenue 5Y
19,3%
CAGR Op. Income 5Y
-43%
CAGR Net Income 5Y
-10,8%
CAGR EPS 5Y
-11,2%
CAGR OCF 5Y
-4,1%
Leverage
N.D./EBITDA
—
Debt/Equity
0%
Current Ratio
2,9
Quick Ratio
2,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!